Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zocor UK Switch Decision Could Be Moved Up

This article was originally published in The Tan Sheet

Executive Summary

The British Department of Health could decide to switch Merck's Zocor (simvastatin) to behind-the-counter status in the UK by late March
Advertisement

Related Content

Merck Zocor Switch Decision In The UK Is Imminent
Merck Zocor Switch Decision In The UK Is Imminent
Merck Zocor Switch Decision In The UK Is Imminent
Rx Firms Keeping A Close Eye On Lagging OTC Market Growth
J&J Increases European Consumer Stake With Merck Buyout
Merck Communicates With UK’s MHRA Over Zocor Switch
Merck Communicates With UK’s MHRA Over Zocor Switch
Merck Remains Active In Pursuit Of Mevacor Rx-to-OTC Switch In U.S.
J&J/Merck Seeking Zocor Switch In UK; Mevacor Still Lead U.S. Candidate
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions

Topics

Advertisement
UsernamePublicRestriction

Register

PS096570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel